Introduction {#Sec1}
============

Pars plana vitrectomy (PPV) is a standard procedure for the treatment of various vitreo-retinal diseases. The sutureless trans-conjunctival approach \[[@CR1]\] has become the standard operating technique and replaced the conventional 20 gauge (G) PPV as the standard procedure in many centers. The smaller sclerotomy (23G or smaller versus 20G) and usually the lack of scleral and conjunctival sutures reduce surgery time and postoperative discomfort \[[@CR2]\]. This presumably might also decrease postoperative inflammation and lead to a faster recovery \[[@CR2]--[@CR5]\]. However, Hikichi et al. reported no significant difference in anterior chamber flare values pre- and 1 week postoperatively between 20G and 23G vitrectomy in a retrospective case series \[[@CR6]\].

The primary purpose of this study was to compare the postoperative inflammation of both surgical approaches in a prospective, randomized and blinded clinical trial. Secondary end points included surgery time, patient discomfort and visual recovery.

Methods {#Sec2}
=======

This prospective, randomized and blinded clinical trial followed the tenets of the Declaration of Helsinki, was approved by the ethics committee of the University of Cologne (UKK-13-247) and was registered as a clinical trial at ClinicalTrials.gov (18 October 2013, NCT01969929). Prior to study inclusion, written informed consent was obtained from all patients. For inclusion, patients had to be 18 years or older, suffer from subjective visual impairment due to a macular hole or macular pucker and be willing to return for a follow-up visit 3 weeks after surgery. Patients with prior vitreoretinal surgery or impaired vision caused by additional eye disease in the study eye were excluded.

All surgeries were performed between October 2013 and May 2015 at the Department of Ophthalmology (University Hospital Cologne, Germany) by four different surgeons, all experienced in 23G as well as 20G vitrectomy. The last follow-up was in November 2015.

Randomization {#Sec3}
-------------

Patients were consecutively informed and screened by the trial physicians. After giving written informed consent, eligible patients were randomly assigned to one of the two treatment groups: 20G or 23G PPV (1:1 allocation). The randomization was stratified by diagnosis (macular hole vs. macular pucker) and lens status (phakic vs. pseudophakic) and implemented by sealed opaque envelopes generated by a statistician on the basis of a computer-generated randomization list (block length 4, concealed during ongoing trial).

Blinding {#Sec4}
--------

All patients and examiners were blinded regarding the assigned surgical procedure.

Flare Measurement {#Sec5}
-----------------

The quantitative measurement of aqueous flare was performed with the Kowa FM-500 Laser Flare-Cell Meter (version 1.0; Kowa Company, Ltd, Tokyo, Japan). The flare values were measured in both eyes 30 min after pupillary dilatation with 0.5% tropicamide and 5% phenylephrine hydrochloride. A minimum of five measurements were performed in each eye and averaged. Measurements with artifacts were excluded. The laser flare values were expressed as photon counts per millisecond (pc/ms). Flare measurements were performed at baseline (V1), 2 days after surgery (V2), 3 weeks after surgery (V3) and 6 months after surgery (V4).

Best-Corrected Visual Acuity {#Sec6}
----------------------------

Best-corrected visual acuity (BCVA) was measured with ETDRS charts at 4 m by a qualified, masked visual acuity examiner at V1, V3 and V4. At each visit a subjective refraction was performed prior to the visual acuity testing.

Astigmatism {#Sec7}
-----------

The minus cylinder from the subjective refraction was used to calculate the mean astigmatism for each visit.

Spherical Equivalent {#Sec8}
--------------------

The spherical equivalent was calculated from the subjective refraction; it was defined as the sum of the spherical value and half of the cylindrical value.

LOCS {#Sec9}
----

The grade of the lens opacification was estimated using the Lens Opacities Classification System III (LOCS III) at V1, V3 and V4 for all phakic patients \[[@CR7]\]. For the analysis, the values of each parameter (nuclear color, nuclear opalescence, cortical, posterior subcapsular) were added.

Patient Discomfort {#Sec10}
------------------

A visual analog scale with values between 0 mm and 100 mm was shown to the patients at each visit. The patients were asked to display the intensity of their discomfort regarding foreign body sensation, burning, pain, itching, photophobia and sticky feeling at the eye.

Surgical Procedure {#Sec11}
------------------

Surgery was performed under local retro-bulbar or general anesthesia. For the PPV, a 23G one-step system or 20G system (EVA Phaco-vitrectomy System, DORC, Zuidland, The Netherlands) was used. A surgical posterior vitreous detachment was induced. Following this, the vitrectomy was performed. ILM peeling was accomplished after fluid-air exchange and ILM staining with 0.025% Brilliant Peel (Geuder, Heidelberg, Germany). The ILM was peeled in the entire macular area. Depending on the underlying disease, the intraocular tamponade was chosen: SF~6~ gas 20% (ISPAN SF~6~ Intraocular Gas; Alcon Pharma GmbH, Freiburg, Germany) for cases with macular holes and balanced salt solution for macular pucker. After 20G PPV, sclerotomies were sutured with Vicryl 7-0, the conjunctiva with Vicyrl 9-0. After 23G PPV, scleral or conjunctival sutures were made only in cases of leaking incisions.

Sample Size {#Sec12}
-----------

The primary end point was the change in aqueous humor flare 3 weeks after surgery (difference from flare at baseline to week 3). A 5-point difference in the flare value (ps/ms) between groups was presumed clinically relevant. A sample size of 84 (2 × 42) would be required to demonstrate a difference of this size. For simplicity reasons, the calculation was based on Student's *t* test \[standard deviation (SD) in each group, derived from previous data collected by the same study group: 8, Student's *t* test, type 1 error rate: 5%, two-sided, power 80%\]. Accounting for stratification by diagnosis and lens status, a total of 100 patients (2 × 50) needed to be randomized.

Calculations were performed with the G\*Power 3.1.2 software (F. Faul, University of Kiel, Germany) \[[@CR8]\].

Statistical Analysis {#Sec13}
--------------------

Efficacy analyses were based on the full analysis set (FAS). The FAS included all randomized patients who underwent eye surgery and who had a valid assessment of the baseline flare. Patients were analyzed as randomized (intention-to-treat principle). The primary end point, change of flare value from baseline to 3 weeks after surgery, was calculated using an analysis of covariance (ANCOVA) with the fixed effects group, diagnosis, lens status, surgeon and baseline flare as a covariant. Missing values were imputed by last observation carried forward (LOCF). The main focus was on the difference in marginal means for the change from baseline to 3 weeks. In a sensitivity analysis, the per-protocol set including all the patients who were treated according to the protocol was employed (i.e., patients for whom no major protocol deviations were documented).

Analysis of secondary end points was mainly descriptive. In addition, key secondary end points BCVA, astigmatism, spherical equivalent and LOCS were analyzed by ANCOVA, such as the primary analysis. Adverse events and aspects of patient comfort were summarized by type. Subgroup analyses regarding diagnosis (macular hole vs. macular pucker) and lens status (phakic vs. pseudophacic) were panned a posteriori. They were essentially explorative (no correction for multiple testing).

Calculations were performed with the SPSS Statistics 23 software (IBM Corp., Armonk, NY, USA).

Results {#Sec14}
=======

One hundred three eyes of 103 patients were randomized for this study. Fifty-one patients were randomized to 20G PPV; all 51 patients were analyzed. Fifty-two were randomized to 23G PPV; 47 of those patients were analyzed for the study. Details are given in the flow diagram (Fig. [1](#Fig1){ref-type="fig"}). All baseline parameters were well balanced between the two groups (Table [1](#Tab1){ref-type="table"}).Fig. 1Flow diagram gives an overview of the randomization process Table 1Preoperative characteristics of all patients (full analysis set)20G (*n* = 51)23G (*n* = 47)*P*\* valueMean age (SD), years68 (7)68 (10)0.596Sex0.546 Male, *n* (%)24 (47)19 (40) Female, *n* (%)27 (53)28 (60)Eye0.225 Right, *n* (%)21 (41)26 (55) Left, *n* (%)30 (59)21 (45)Stratification by diagnosis and lens status (randomization), *n* (%) Macula hole, phakic eye15 (29.4)12 (25.5)0.983 Macula hole, pseudophakic eye8 (15.7)7 (14.9) Macular Pucker, phakic eye18 (35.3)18 (38.6) Macular Pucker, pseudophakic eye10 (19.6)10 (21.3)Diagnosis0.686 Macula hole23 (45.1)19 (40.4) Macular pucker28 (55.0)28 (59.6)Lens status0.835 Phakic eye33 (64.7)29 (61.7) Pseudophakic eye18 (35.3)18 (38.3)Macular hole diameter (µm)\*\*383 (160)343 (132)0.519*SD* standard deviation, *20G* 20 gauge vitrectomy, *23G* 23 gauge vitrectomy\**p* values are from Fisher's exact test (qualitative data) or Kruskal-Wallis test (quantitative data), respectively\*\*Macular hole diameter was available for all 23 patients with macular hole in the 20G group and all 19 patients in the 23G group respectively

Aqueous Flare {#Sec15}
-------------

The primary end point, the change of aqueous humor flare 3 weeks after surgery, did not differ between 20G and 23G PPV \[20G: 3.5 ± 9.5, 23G: 2.3 ± 13.2; mean difference between groups: − 1.7, 95% CI (− 6.3 to 2.9), *p* = 0.466\]. Nevertheless, both groups showed a significant increase in flare values (in pc/ms) 2 days after surgery. In the 20G group, the flare value was still significantly higher 3 weeks after surgery. At week 26, flare values were at baseline level in both groups. (20G: baseline: 9.4 ± 6.2, day 2: 19.1 ± 13.0, *p* \< 0.001, week 3: 12.9 ± 9.9, *p* = 0.011, week 26: 10.0 ± 5.4, *p* = 0.490; 23G: baseline: 8.8 ± 7.3, day 2: 19.4 ± 22.0, *p* = 0.002, week 3: 11.1 ± 14.6, *p* = 0.246, week 26: 10.6 ± 21.8, *p* = 0.576). See Table [2](#Tab2){ref-type="table"} for the evaluation of primary and key secondary end points, Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} of the supplement for additional evaluation of the day 2 and week 26 parameters. Supplemental Table 3 displays the results of the evaluation of the primary and key secondary end point based on the per-protocol set.Table 2Evaluation of primary and key secondary end points based on the full analysis set (analysis according to intention-to-treat principle, last observation carried forward; mean (SD) unless stated otherwise; results for per-protocol set are given in the supplement)ParameterGroupBaselineWeek 3Week 26 (after 6 months)Difference week3---baselineDifference week26---baselinePaired *t* test, 95% CI (week3---baseline)Paired *t* test, 95% CI (week26---baseline)ANCOVA^d^ 20G vs. 23G, difference at week3 (95% CI)Flare^a^20G (*n* = 51)9.4 (6.2)12.9 (9.9)10.0 (5.4)3.5 (9.5)0.6 (6.0)0.8 to 6.1*p *= 0.0111.1 to 2.3*p *= 0.49023G (*n* = 47)8.8 (7.3)11.1 (14.6)8.6 (7.5)2.3 (13.2)− 0.3 (3.5)− 1.6 to 6.1*p *= 0.246− 1.3 to 0.7*p *= 0.576− 1.7 (− 6.3 to 2.9)*p *= 0.466BCVA, ETDRS^b^20G (*n* = 51)54.4 (15.4)58.6 (13.1)65.4 (11.8)4.2 (10.4)11.0 (13.5)1.3 to 7.1*p *= 0.0057.2 to 14.8*p *\< 0.000123G (*n* = 47)59.3 (13.0)66.1 (12.3)66.6 (14.9)6.8 (10.4)7.3 (15.6)3.7 to 9.8*p* \< 0.00012.7 to 11.9*p* = 0.0034.2 (0.4 to 8.0)*p *= 0.029Astigmatism20G (*n* = 51)− 0.9 (0.7)− 1.2 (1.0)− 1.0 (0.7)− 0.3 (0.9)− 0.1 (0.6)− 0.5 to − 0.03*p *= 0.027− 0.3 to 0.1*p *= 0.30223G (*n* = 47)− 0.9 (0.8)− 0.9 (0.8)− 1.0 (0.8)0.1 (0.6)− 0.1 (0.9)− 0.1 to − 0.2*p *= 0.444− 0.3 to 0.2*p *= 0.5100.3 (0.03 to 0.62*p *= 0.028Spherical equivalent20G (*n* = 51)− 0.5 (2.2)− 0.9 (2.7)− 2.0 (2.6)− 0.3 (1.6)− 1.4 (1.6)− 0.8 to 0.1*p *= 0.161− 1.9 to − 1.0*p *\< 0.00123G (*n* = 47)− 0.9 (2.8)− 1.0 (2.9)− 1.8 (3.6)− 0.1 (0.7)− 0.9 (1.8)− 0.3 to 0.1*p *= 0.230− 1.4 to − 0.4*p *= 0.0010.2 (0.31 to 0.70*p *= 0.440LOCS (sum of 4)^c^20G (*n* = 32)5.3 (1.8)5.8 (1.7)8.3 (2.2)0.4 (0.8)2.9 (2.4)0.1 to 0.6*p *= 0.0022.1 to 3.8*P *\< 0.00123G (*n* = 28)5.2 (1.2)5.5 (1.5)8.0 (2.2)0.4 (0.6)2.9 (2.3)0.1 to 0.6*p *= 0.0022.0 to 3.8*P *\< 0.001− 0.1 (− 0.4 to 0.3)*p *= 0.757*SD* standard deviation, *CI* confidence interval, *Flare* aqueous flare in photon counts per millisecond, *20G* 20 gauge vitrectomy, *23G* 23 gauge vitrectomy^a^Flare at week 3 was available for 48 of 51 (20G) and 43 of 47 patients (23G), respectively. Flare at week 26 was available for 40 of 51 (20G) and 35 of 47 patients (23G), respectively^b^ETDRS at week 3 was available for 50 of 51 (20G) and 45 of 47 patients (23G), respectively. ETDRS at week 26 was available for 43 of 51 (20G) and 36 of 47 patients (23G), respectively^c^LOCS values were only available for phakic patients^d^Adjusted for baseline value

Best-Corrected Visual Acuity {#Sec16}
----------------------------

Both groups experienced a significant gain in ETDRS letters after surgery. At the week 3 visit, the increase was higher after 23G PPV (20G: 4.2 ± 10.4, 23G: 6.8 ± 10.4, *p* = 0.029), but it showed no significant difference at the 6-month visit (Table [2](#Tab2){ref-type="table"}).

Astigmatism {#Sec17}
-----------

The change in astigmatism was higher 3 weeks after 20G compared with 23G surgery (20G: − 0.3 ± 0.9, 23G: 0.1 ± 0.6 *p* = 0.028), but revealed no difference 6 months after surgery (Table [2](#Tab2){ref-type="table"}).

Spherical Equivalent {#Sec18}
--------------------

The spherical equivalent did not show a significant change 3 weeks after surgery in either group (Table [2](#Tab2){ref-type="table"}), but decreased significantly after 6 months in both groups (20G: − 0.1 ± 0.6, *p* \< 0.001, 23G: − 0.1 ± 0.9, *p* = 0.001) without a relevant difference between the groups (Table [2](#Tab2){ref-type="table"}).

LOCS {#Sec19}
----

The degree of the lens opacification, assessed using the LOCS scale, increased significantly 3 weeks and 6 months after surgery in both groups, without a difference between the groups (Table [2](#Tab2){ref-type="table"}).

Surgery Duration {#Sec20}
----------------

The mean duration of surgery was shorter in the 23G group (20G: 29 ± 6 min, 23G: 20 ± 6 min, *p* \< 0.001). Details regarding the surgery duration and other intra- and postoperative outcomes are given in Table [3](#Tab3){ref-type="table"}.Table 3Evaluation of intra- and postoperative outcomes/end points (mean (SD) unless stated otherwise)Evaluation of all diagnoses20G (*n* = 51)23G (*n* = 47)*P*\* valueDuration of surgery, min29 (6)\*\*20 (6)\*\*\< 0.001 Range17--4710--35 Median (IQR)28 (8)20 (8)Preoperative IOP, mmHg15.0 (3.8)15.4 (3.50)0.444IOP postoperative, surgery day mmHg16.9 (8.2)\*\*12.5 (6.2)\< 0.001IOP day 2, mmHg13.4 (4.1)11.6 (4.5)0.005IOP week 3, mmHg16.5 (5.1)\*\*16.7 (5.5)\*\*0.929IOP month 6, mmHg14.8 (3.6)\*\*15.3 (3.7)\*\*0.747Days of hospitalization2.1 (0.6)1.9 (0.5)0.276 Range1--31--3Patients with macular hole only20G (*n* = 23)23G (*n* = 19)*p*\* valueForamen status0.384 Foramen closed21 (91)15 (79) Persistent macular hole2 (9)4 (21)*IOP* intraocular pressure, *SD* standard deviation, *20G* 20 gauge vitrectomy, *23G* 23 gauge vitrectomy\**p* values are from Fisher's exact test (qualitative data) or Kruskal-Wallis test (quantitative data), respectively\*\*Duration of surgery was available for 50 of 51 (20G) and 47 of 47 patients (23G), respectively. \*\*IOP at week 3 was available for 50 of 51 (20G) and 45 of 47 patients (23G), respectively. \*\*IOP at week 26 was available for 33 of 51 (20G) and 26 of 47 patients (23G), respectively

Sutures {#Sec21}
-------

After 20G surgery, all conjunctival and scleral incisions were sealed with sutures as a standard feature. In the 23G group, in six patients the surgeon decided to make scleral sutures and in ten patients conjunctival sutures because of leaking incisions.

Intraocular Pressure (IOP) {#Sec22}
--------------------------

The postoperative IOP was lower after 23G PPV (surgery day: 20G: 16.9 ± 8.2 mmHg, 23G: 12.5 ± 6.2 mmHg, *p* \< 0.001; day 2: 20G: 13.4 ± 4.1, 23G: 11.6 ± 4.5, *p* = 0.005), but matched after 3 weeks (*p* = 0.929). See Table [3](#Tab3){ref-type="table"} for details. The rate of postoperative hypertension was higher after 20G PPV (*p* = 0.033) but the rate of postoperative hypotension did not differ between the groups. See Table [4](#Tab4){ref-type="table"}.

Safety and Patient Comfort {#Sec23}
--------------------------

Most analyzed parameters concerning the patient comfort showed no significant difference between 20G and 23G surgery (Table [4](#Tab4){ref-type="table"}). A clear benefit of the 23G system was only apparent regarding the foreign body sensation 2 days and 3 weeks after surgery (day 2: 20G: 29 ± 24, 23G: 13 ± 19, *p* \< 0.001; week 3: 20G: 22 ± 24, 23G: 9 ± 14, *p* = 0.002) and itching 3 weeks after surgery (20G: 12 ± 20, 23G: 5 ± 10, *p* = 0.021). In Table [5](#Tab5){ref-type="table"}, all results of the visual analog scale for patient discomfort are shown.Table 4Tabulation of adverse events (by patient, *n* (%))Category20G (*n* = 51)23G (*n* = 47)Number of AEs3524Number of patients with at least 1 AE28 (55)18 (38)Postoperative hypertension(30 mmHg)\*13 (25)4 (9)Iatrogenic retinal breaks10 (20)4 (9)Steroid response (3 weeks after surgery)3 (6)4 (9)Postoperative hypotension (≤ 5 mmHg)2 (4)4 (9)Cataract surgery (within 6 months)3 (6)2 (4)Retinal detachment2 (4)1 (2)CNV0 (0)1 (2)Endopthalmitis0 (0)0 (0)*AE* adverse event, *CNV* choroidal neovascularization, *20G* 20 gauge vitrectomy, *23G* 23 gauge vitrectomy\**p* = 0.033 from Fisher's exact test Table 5Patient comfort \[measured with a visual analog scale; mean (SD)\]ItemTime20G (*n* = 51†)23G (*n* = 47†)Foreign body sensationBaseline13 (21)9 (21)Day 2\*29 (24)13 (19)Week 3\*\*22 (24)9 (14)Month 67 (19)6 (16)PainBaseline4 (13)2 (7)Day 2\*\*\*10 (18)6 (10)Week 36 (11)4 (14)Month 64 (15)2 (10)BurningBaseline8 (15)7(15)Day 215 (20)8 (16)Week 310 (19)8 (17)Month 67 (17)5 (17)ItchingBaseline14 (18)9 (17)Day 26 (11)6 (12)Week 3^+^12 (20)5 (10)Month 66 (17)3 (7)Sticky feeling at the eyeBaseline8 (15)7 (15)Day 224 (26)15 (20)Week 313 (21)8 (14)Month 68 (18)4 (10)PhotophobiaBaseline24 (28)30 (32)Day 224 (28)23 (26)Week 323 (27)27 (30)Month 6^++^15 (25)29 (37)*SD* standard deviation, *20G* 20 gauge vitrectomy, *23G* 23 gauge vitrectomy^a^Completed forms were missing at day 2 for 1 patient (20G), at week 3 for 4 patients (1 in 20G and 3 in 23G) and at week 26 for 19 patients (8 in 20G and 11 in 23G). \**p* \< 0.001, \*\**p* = 0.002, \*\*\**p* = 0.06, ^+^*p* = 0.021, ^++^*p* = 0.050 (derived from *t* test)

At least one adverse event occurred in 28 of 51 patients (55%) in the 20G group and in 18 from 47 (38%) in the 23G group. The most common AE in both groups was postoperative hypertension, which appeared significantly more often after 20G PPV (*p* = 0.033). The rate of all other adverse events did not differ between the groups. Table [4](#Tab4){ref-type="table"} gives an overview of the number and types of adverse events in both groups.

Subgroup Analysis {#Sec24}
-----------------

The analysis of the primary and key secondary end points for the subgroups (phakic/pseudophakic and macular hole/macular pucker) showed a statistically significant difference regarding visual acuity between the treatments for the subgroup of pseudophakic patients (9.3, 95% CI 3.4 to 15.2; *p* = 0.003) as well as for the subgroup of patients with macular pucker (4.7, 95% CI 0.3 to 9.1; *p* = 0.037). Pseudophakic patients as well as patients with macular pucker profited more from the 23G PPV. Regarding postoperative inflammation, none of the subgroups showed a statistically significant difference between the treatment groups. Pseudophakic patients treated with 23G PPV had a lower flare value after 3 weeks than patients treated with 20G PPV, although this was not statistically significant \[− 3.0 95% CI (− 6.2 to 0.3); *p* = 0.070\]. The flare value in the 23G group was still lower after 26 weeks (11.1 ± 11.3) compared with 20G (12.2 ± 6.6), (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, Supplemental Table 4).Fig. 2Forest plots for the subgroup analysis regarding the change in flare values from baseline to week 3. 23G vitrectomy is favored in all subgroups.*BCVA* best corrected visual acuity,*flare* aqueous flare in photon counts per millisecond;*20G* 20 gauge vitrectomy,*23G* 23 gauge vitrectomy Fig. 3Forest plots for the subgroup analysis regarding the change in EDTRS letters from baseline to week 3. 23G vitrectomy is favored in all subgroups.*BCVA* best corrected visual acuity,*ETDRS* early treatment diabetic retinopathy study,*20G* 20 gauge vitrectomy,*23G* 23 gauge vitrectomy

Discussion {#Sec25}
==========

The transconjunctival 23G PPV has become a standard procedure in many centers. Possible advantages could be less postoperative inflammation, a shorter duration of surgery and greater patient comfort due to smaller incisions and a sutureless approach \[[@CR2]--[@CR4], [@CR9]\]. However, the data published so far are inconsistent, and most studies have major limitations such as lack of randomization, retrospective study design, lack of blinding of patients and non-uniform surgery indications.

In this randomized and blinded clinical trial, postoperative inflammation, visual outcome and patient comfort were compared between 20G versus 23G PPV. There was no statistically significant difference in aqueous humor flare values between the two groups 3 weeks after surgery, and therefore the primary end point was not met. However, inflammation decreased faster in the 23G group. Also, the subgroup analysis showed that pseudophakic patients favored 23G PPV over 20G PPV, although the difference was not significant (Fig. [2](#Fig2){ref-type="fig"}).

Hence, it appears that the inflammation caused by the actual surgery is more or less similar in 20G and 23G PPV, but regarding the 20G PPV, there seems to be a remaining inflammation stimulus after surgery, which could be responsible for the extended increase in flare values beyond the week 3 visit. The most probable explanation for the slower decrease in inflammation after 20G PPV is the sutures used in 20G PPV to seal the incisions. Although the used material (vicryl) is usually well tolerated, it is still a foreign body that can induce inflammation in the eye. Also, the larger incision itself could be responsible for the slower decrease in postoperative inflammation after 20G PPV.

So, even if there might be a scant but quantifiable advantage for the 23G PPV regarding the postoperative inflammation, since the effect is only short term, it is highly questionable if this leads to any relevant benefit for the daily clinical practice.

Rizzo et al. \[[@CR10]\] reported a lower postoperative inflammation 1 day and 1 week after sutureless small-incision PPV, but they compared 25G and 20G PPV, using a subjective semiquantitative score to classify the degree of postoperative inflammation. Therefore, the results are not quite comparable to our findings. Hikichi et al. also reported increased flare values 1 week after 20G and 23G surgery in a retrospective case series, but they did not find a difference between the two groups \[[@CR6]\]. Unfortunately, they did not publish any flare data measured later than 1 week after surgery.

In addition to the aqueous flare, we also looked into visual acuity improvement after surgery. This was faster after 23G PPV, but without a better visual acuity at the last visit after 26 weeks.

This finding is in line with data published by Hikichi et al. \[[@CR6]\] and Narayanan et al. \[[@CR11]\]. Most authors ascribed the faster visual recovery to the lower early postoperative corneal astigmatism after small-incision surgery, which was reported in different studies \[[@CR6], [@CR12], [@CR13]\] and also confirmed by our work. Furthermore, the increased anterior chamber inflammation found in the 20G group 3 weeks after surgery could be an additional reason for the slower visual recovery.

A clear advantage of the small-incision PPV is the shorter surgery time. Similar to other studies \[[@CR3], [@CR4]\], 23G PPV shortened the surgery duration in our cohort significantly. The reduction of the surgery time by a mean of 9 min per patient can likely compensate for the higher costs of the 23G PPV set at least partially by lowering the costs of surgery staff and the time in the surgery room.

Another potentially relevant advantage of the 23G technique is the better postoperative patient comfort and less postoperative pain. A faster recovery is not only a matter of personal comfort but could also be an economic factor regarding the number of sick days after surgery. However, postoperative pain values were very low in both groups and did not differ significantly between the groups. Nevertheless, patients in the 23G group had significantly less foreign body sensation, eye burning and sticky feeling in the early postoperative phase, which could be explained by the lack of sutures after 23G PPV. However, the greater postoperative comfort did not lead to a shorter duration of hospitalization in our cohort. Likewise, Mentens et al. did not find a difference regarding the number of sick days after surgery between 20G and 23G PPV despite the greater patient comfort after sutureless PPV in their study \[[@CR2]\].

With the introduction of the small-incision surgery, surgeons not only hoped for an easy and fast-to-perform technique, but also for fewer complications, since the technique seems to be gentler and less invasive.

A postoperative IOP rise is a common finding after PPV \[[@CR14]\]. Gosse et al. found a higher rate of IOP elevation after 20G compared with 23G PPV in a retrospective case series \[[@CR15]\].

In our study, we also found a statistically significantly higher IOP after 20G PPV. Additionally, the risk of postoperative IOP elevation ≥ 30 mmHg was significantly higher after 20G PPV. Although the postoperative hypertension is usually transient, the management normally includes local or even systemic IOP-lowering medication and more frequent examination visits. Even if the hypertension is treated successfully after detection, also a transient hypertensive episode can potentially lead to long-term damage. The risk might be especially high for patients after outpatient surgery when the interval between the appearance of the hypertension and detection by the ophthalmologist can be prolonged.

Furthermore, an idea could be that a lower early postoperative pressure, as found after 23G PPV, reduces the risk of long-term glaucoma development. However, so far, whether PPV increases the risk of glaucoma \[[@CR16]\] and if the risk is lower after 23G surgery have not been clarified yet. In our cohort, all patients with postoperative hypertension could be temporarily treated with local or systemic anti-glaucoma drugs without long-term complications during the 6-month follow-up period. The lower risk ofor postoperative hypertension after 23G PPV could be accompanied by a higher rate of postoperative hypotension as reported by Haas et al. We could not see this effect in our study; the occurrence of postoperative hypotension did not differ between the two surgery techniques.

The most feared complications after PPV are postoperative endophthalmitis and retinal detachment. Like other studies \[[@CR4], [@CR6]\], we could not detect any difference in the appearance of those complications. Additionally, the rate of patients with any AE and the overall number of AEs did not differ between the groups.

A typical side effect of PPV in phakic patients is cataract formation \[[@CR17], [@CR18]\]. We also saw a low but significant increase in LOCS values as early as week 3 and a much more distinct increase 6 months after surgery in our patients. We also observed a shift of the spherical equivalent toward minus in both groups during the observational period. This is most likely caused by a myopic shift due to the cataract formation. It is conceivable that the shorter surgery duration in the 23G group leads to a lower stimulation of cataract formation. However, we did not find any difference in the degree of cataract development between the two groups. Besides, there was also no difference in the number of patients with the need for cataract surgery within the first 6 months after surgery.

Not really a complication, but nevertheless an important surgical outcome, is the closure rate of macular holes. We found no significant difference in the closure rate of macular holes between the two groups. Also Krishnan et al. did not find different closure rates after 20G and 23G PPV in a retrospective case series \[[@CR5]\].

Limitations of our study are the lack of evaluation visits between week 3 and week 26. Therefore, we are not able to narrow down the time frame with increased flare values for the different groups. Additionally, the cohort is too small to perform convincing statistical analysis for the subgroups (macular hole, macular pucker with subdivision in phakic and pseudophakic). Our subgroup analyses show that pseudophakic patients as well as patients with macular pucker profit more from the 23G PPV regarding visual outcome (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). With respect to postoperative inflammation, none of the subgroups showed a statistically significant difference between the treatment groups. Due to small subgroups and therefore wide confidence intervals, only a trend toward lower flare values after 23G PPV could be shown in pseudophakic patients.

Conclusions {#Sec26}
===========

In conclusion, the primary aim of this trial, the superiority of the 23G PPV regarding the change of flare value from baseline to 3 weeks after surgery, could not be shown. However, the level of inflammation decreases faster after 23G PPV. Nevertheless, clear advantages of the 23G PPV are a lower risk for postoperative IOP elevation, a shorter surgery time, faster visual recovery and a greater patient comfort in the early postoperative phase.
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